logo
logo

SpectraWAVE Announces $13.2 Million Series A-2 Financing from Existing Investors to Bring Intracoronary Imaging Technology to Market

Feb 03, 2021•over 4 years ago

Amount Raised

$13.2 Million

Round Type

series a

Bedford

Description

SpectraWAVE, Inc. today announced a $13.2 million Series A-2 financing to support completion of product development and regulatory filing for its flagship intracoronary imaging product, designed to help physicians optimize coronary stenting interventions and limit future adverse events. The funding round is led by prior investor Deerfield Management, and includes follow-on investment from prior unnamed seed investors.

Company Information

Company

Spectra Wave, Inc.

Location

Bedford, Pennsylvania, United States

About

SpectraWAVE, located in Bedford, MA, is a privately held medical device company founded in 2017 to improve coronary artery disease (CAD) outcomes with photonics. CAD, the buildup of plaque in the wall of the arteries that supply blood to the heart, affects 18.2 million adults age 20 and older. In CAD patients that undergo percutaneous stent placement, it is estimated that one in five patients experience adverse events, with half of those adverse events caused by high risk plaques that were previously left untreated. The SpectraWAVE medical imaging platform is a state-of-the-art integration of proven imaging technologies - designed to help interventional cardiologists understand their patients and optimize interventions. For more information, please visit www.spectrawave.com.

Related People

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech